RhumbLine Advisers’s Acumen Pharmaceuticals ABOS Stock Holding History

RhumbLine Advisers’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$165K	Buy	74,134 +39,100	+112%	+$101K	﹤0.01%	3350
2026 Q2	$93.5K	Buy	+35,034	New	+$86.5K	﹤0.01%	3554
2025 Q2	–	Sell	-45,516	Closed	-$50.1K	–	4139
2025 Q1	$50.1K	Sell	45,516 -7,560	-14%	-$10.8K	﹤0.01%	3576
2024 Q4	$91.3K	Sell	53,076 -35,408	-40%	-$85.3K	﹤0.01%	3502
2024 Q3	$219K	Buy	88,484 +36,161	+69%	+$98.1K	﹤0.01%	3191
2024 Q2	$127K	Buy	+52,323	New	+$167K	﹤0.01%	3438
2022 Q2	–	Sell	-20,273	Closed	-$79K	–	3085
2022 Q1	$79K	Buy	+20,273	New	+$110K	﹤0.01%	2930

Other funds holding ABOS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Catalyst Financial Partners Boston, Massachusetts $1.07B AUM 26.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

RhumbLine Advisers's ABOS Position: Q3 2026 in Review

RhumbLine Advisers increased its Acumen Pharmaceuticals (ABOS) stake by 112% in Q3 2026, buying an estimated $101K and bringing the position to 74,134 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #3350.

RhumbLine Advisers first reported a position in ABOS in Q1 2022 and has held it in 7 quarters since. The position peaked at $219K in Q3 2024. 37 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

RhumbLine Advisers held 74,134 shares of Acumen Pharmaceuticals worth $165K as of Q3 2026.
RhumbLine Advisers bought 39,100 Acumen Pharmaceuticals shares in Q3 2026, an estimated $101K.
Acumen Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3350 holding.
RhumbLine Advisers first reported a position in Acumen Pharmaceuticals in Q1 2022 and has held it in 7 quarters since.
RhumbLine Advisers's Acumen Pharmaceuticals position peaked at $219K in Q3 2024.
37 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.